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Abstract
Background: Since the late 1980s a series of malaria epidemics has occurred in western Kenya
highlands. Among the possible factors that may contribute to the highland malaria epidemics,
parasite resistance to antimalarials has not been well investigated.
Methods: Using parasites from highland and lowland areas of western Kenya, we examined key
mutations associated with Plasmodium falciparum resistance to sulfadoxine – pyrimethamine and
chloroquine, including dihydrofolate reductase (pfdhfr) and dihydropteroate synthetase (pfdhps),
chloroquine resistance transporter gene (pfcrt), and multi-drug resistance gene 1 (pfmdr1).
Results: We found that >70% of samples harbored 76T pfcrt mutations and over 80% of samples
harbored quintuple mutations (51I/59R/108N pfdhfr and 437G/540E pfdhps) in both highland and
lowland samples. Further, we did not detect significant difference in the frequencies of these
mutations between symptomatic and asymptomatic malaria volunteers, and between highland and
lowland samples.
Conclusion: These findings suggest that drug resistance of malaria parasites in the highlands could
be contributed by the mutations and their high frequencies as found in the lowland. The results are
discussed in terms of the role of drug resistance as a driving force for malaria outbreaks in the
highlands.
Background
Malaria is a major public health problem in sub-Saharan
Africa and Plasmodium falciparum infection is a leading
cause of morbidity and mortality inflicting a huge eco-
nomic burden in countries where the disease is endemic
[1]. It is estimated that death toll of malaria exceeds one
million people each year, and the victims are primarily
children under the age of five [2]. Until the early 1980s,
the African highlands (generally referred to areas of
>1,500 m above sea level) were either free of malaria or
had very low incidences of the disease; however, since the
late 1980s a series of malaria epidemics has occurred [3-
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9]. Among the many factors that may contribute to the
highland malaria epidemics, resistance of the parasites to
multiple antimalarials has not been extensively investi-
gated. Resistance to antimalarial drugs is one of the major
obstacles for effective malaria control. The first case of
chloroquine (CQ) resistance in Kenya was reported in
1977 [10]. In 1993, resistance levels had reached 70%
[11]. In 1998, the Ministry of Health of Kenya changed
the first line of treatment from chloroquine to sulfadoxine
– pyrimethamine (SP; Fansidar®) [12]. In 2004, the Min-
istry of Health of Kenya officially changed the first-line
drug to artemether/lumefantrin (Coartem™) [13].
Drug resistance in malaria parasites is associated with
genetic mutations in target genes and can be monitored
using molecular methods. CQ resistance is determined by
the major point mutation at codon 76 of the P. falciparum
CQ resistance transporter (pfcrt) gene [14], which is highly
correlated with increased clinical CQ tolerance and treat-
ment failure [14-16]. In addition, point mutations in P.
falciparum  multi-drug resistance gene 1 (pfmdr1) (e.g.,
N86Y, Y183F, S1034C, N1042D, and D1246Y) have been
shown to modulate CQ resistance [17] and possibly lume-
fantrine resistance [18]. Resistance to antifolates is associ-
ated with point mutations in the dihydrofolate reductase
(pfdhfr) and dihydropteroate synthetase (pfdhps) genes
[19]. Pyrimethamine (PY) resistance is conferred by the
key mutation at codon 108 in the pfdhfr gene, while addi-
tional mutations at positions 51 and 59 increase the levels
of resistance [20]. The 164L mutation common in South-
east Asia has been shown to confer PY resistance.
Although this mutation is not common in Africa, a recent
study by McCollin et al detected the 164L mutation in
western Kenya [21]. Similarly, sulfadoxine (SD) resistance
is conferred by a key mutation at codon 437 in the pfdhps
gene and modulated by additional mutations at codons
436, 540, 581, and 613 [22]. Multiple mutations in these
two genes result in antifolate treatment failure [23].
Molecular methods have been developed to detect point
mutations in genes responsible for drug resistance [24-
26], and have been widely used to monitor drug resistance
in epidemiological surveys [16]. In this study, we have
analyzed the mutations of antimalarial drug resistance
genes for CQ (pfcrt and pfmdr1) and antifolates (pfdhps
and pfdhfr) in samples from patients with acute malaria
infections and school children with asymptomatic infec-
tions at one lowland and two highland locations in west-
ern Kenya.
Methods
Sample collection
Sampling in two highland sites (Kisii, elevation ~1600 m
above sea level; and Kakamega, elevation 1,480–1,560 m)
and one neighboring lowland site (Kombewa, elevation
~1200 m) from June through August 2005 were con-
ducted as a part of malaria surveillance activities. Average
annual malaria prevalence among primary school chil-
dren during the sampling period was 10.3%, 42.7% and
75% in Kisii, Kakamega and Kombewa, respectively.
Malaria transmission intensity, measured by entomologi-
cal inoculation rate (EIR), was 0.4, 16.6 and 31.1 infec-
tious bites per person per year in Kisii, Kakamega and
Kombewa, respectively [27]. At each site, 100 samples
were collected from patients admitted with acute P. falci-
parum infection at a local hospital and 100 samples from
primary school children (age 6–14 years old) with asymp-
tomatic P. falciparum infections diagnosed by microscopy.
Symptomatic malaria patients were treated by clinicians
in the hospital with antimalarial drug, Coartem which
achieved cure rates of up to 95%, even in areas of multi-
drug resistance. Each sample consisted of ~200 μl of fin-
ger-prick blood spotted on filter papers. Filter papers were
dried and stored at -20°C until parasite DNA extraction.
The human subject protocol involved in this study has
been approved by University of California, Irvine (UCI)
and Kenya Medical Research Institute (KEMRI). Informed
consent was provided by the parents/guardians of the
children and assent from the children was obtained prior
to the sample collection.
Parasite DNA extraction and species identification
DNA was extracted from the blood filters using the
Saponin/Chelex method [28]. Parasite DNA was extracted
from one quarter of a blood spot of about 1 cm in diame-
ter and dissolved in 200 μl of distilled water. Three micro-
liters of the parasite DNA were used as the template for
polymerase chain reaction (PCR). To avoid complications
from mixed parasite species infections, a nested PCR
method was used to verify P. falciparum infections and
exclude the presence of other Plasmodium species in each
sample [29]. Approximately 3–5% of samples containing
mixed parasite species or other parasite species were iden-
tified in all the study sites. Samples containing only P. fal-
ciparum DNA were used for genotyping analysis.
Molecular detection of mutations in drug targets
Mutations in the pfcrt  (K76T) and pfmdr1  genes were
detected using a PCR-restriction fragment length poly-
morphism (RFLP) method. The fragment encompassing
pfcrt  codon 76 was amplified and digested with ApoI,
which cleaves the wild type into 111 and 34 bp fragments
[30]. Similarly, fragments containing codons 86, 184,
1034, 1042, and 1246 of the pfmdr1 gene were separately
amplified by PCR and digested with respective restrictive
enzymes as described previously [30-33]. Screening for
mutations associated with antifolate resistance at codons
16, 50, 51, 59, 108, and 164 of the pfdhfr gene and
codons 436, 437, 540, 581, and 613 of the pfdhps gene
was performed by nested PCR and mutation-specific
restriction enzyme digestions [34-36].BMC Infectious Diseases 2008, 8:105 http://www.biomedcentral.com/1471-2334/8/105
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Statistical analysis
The difference in frequencies of point mutations in the
four aforementioned genes between highland and low-
land parasite populations was determined by using the χ2
tests or Fisher's exact test for datasets with sample size less
than 5. Yates' correction was applied for the chi-square
value, resulting in corrected P values. Statistical signifi-
cance was taken at the P = 0.05 level. Association between
the different mutations was tested using Fisher's exact test.
Results
A total of 600 P. falciparum samples were analyzed for
pfcrt, pfmdr1, pfdhfr, and pfdhps genes. Over 90% of sam-
ples were successfully amplified at the 17 test codons, and
polymorphisms were detected at 10 of 17 codons
screened (Table 1). Consistent with the hyperendemic set-
tings in the study areas, we detected infections by mixed
strains at seven of the 17 studied codons, which included
codon 76 of pfcrt, codons 86, 184 and 1246 of pfmdr1,
codon 59 of pfdhfr, and codons 437 and 540 of pfdhps
(Table 1). The frequencies of mutant codons at the four
genes varied slightly between the study sites, but the dif-
ferences were not significant (Fig. 1). Mixed-genotype
infections at pfdhfr codon 59, 437, and 540 of the anti-
folate target genes were low (<10%) in all samples. Simi-
larly, mixed-genotype infections at codon 76 of the pfcrt
gene were low (<15%). In contrast, mixed-genotype infec-
tions at codons 86, 184 and 1246 of the pfmdr1 gene were
more frequent (18 – 45%) (Table 1).
Mutations in CQ resistance genes
Consistent with the past extensive use of CQ in this area,
the pfcrt 76T mutant allele was present in = 80% (includ-
ing mixed infections with wild type and mutant alleles) of
all samples from the three locations (Fig. 1A and 1B). In
comparison, mutations at alleles 86Y, 184F and 1246Y of
Table 1: Frequencies of mutations in genes associated with resistance to chloroquine, sulfadoxine-pyrimethamine in P. falciparum 
parasites from symptomatic and asymptomatic volunteers in western Kenya.
Gene Mutation Polymorphism Kombewa Kakamega Kisii
S* A* S A S A
pfcrt K76T Mutant 87 81 86 77 75 70
Mixed 7 15 6 9 8 10
Wild-type 6 4 8 14 17 20
Pfmdr1 N86Y Mutant 28 41 28 39 10 23
M i x e d 4 42 24 53 74 0 1 8
W i l d - t y p e 2 83 72 72 45 0 5 9
Y184F Mutant 24 15 7 5 11 26
M i x e d 2 63 02 32 63 3 1 9
W i l d - t y p e 5 05 57 06 95 6 5 5
D1246Y Mutant 24 37 40 28 42 24
M i x e d 4 23 03 64 42 1 2 9
W i l d - t y p e 3 43 32 42 83 7 4 7
pfdhfr N51I Mutant 98 96 98 98 96 95
M i x e d 00000 0
W i l d - t y p e 24224 5
C59R Mutant 81 75 88 79 90 86
Mixed 4 10 2 7 2 0
W i l d - t y p e 1 51 51 01 481 4
S108N Mutant 100 100 100 100 100 100
M i x e d 00000 0
W i l d - t y p e 00000 0
pfdhps S 4 3 6 F M u t a n t 42442 2
M i x e d 00000 0
W i l d - t y p e 9 69 89 69 69 8 9 8
A437G Mutant 94 95 92 93 88 93
M i x e d 45472 0
W i l d - t y p e 2040 1 0 7
K540E Mutant 88 95 92 91 88 93
M i x e d 1 0 5492 0
W i l d - t y p e 2040 1 0 7
* S – symptomatic; A – asymptomatic.
Note: No mutations were detected at the following codons: pfdhfr (A16V, C50R and I164L); pfdhps (S436A, A581G and A613S); and pfmdr1 (S1034 
and N1042D).BMC Infectious Diseases 2008, 8:105 http://www.biomedcentral.com/1471-2334/8/105
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pfmdr1 gene were present at lower frequencies, ranging
from 30 to 76% (including mixed infections) (Fig. 1C and
1D), whereas no mutation was found at codons 1034 and
1042, which was associated with CQ resistance in South
America. The frequencies of mutations were generally not
significantly different between the three study sites except
pfcrt 76T and pfmdr1 86Y between Kombewa and Kisii (P
< 0.05), and pfmdr1  184F between Kombewa and
Kakamega (P < 0.01) (Fig. 1E and 1F). Consequently, the
genotype 86Y/184Y/1246Y (wildtype at codon 184) was
present at a significantly higher frequency in highland
than in lowland parasites (P < 0.05), whereas the geno-
type 86Y/184F/1246Y (triple mutations) was significantly
more frequent in lowland than in highland parasites
(Table 2). Since certain pfmdr1 alleles were found associ-
ated with CQ resistance, we compared the association
between pfmdr1 mutations and the major CQ-resistance
determinant pfcrt  76T. When all parasite samples were
taken into account, significant associations were found
between the pfcrt 76T and two pfmdr1 alleles (184F and
1246Y) (P < 0.01). However, pfcrt 76T was not signifi-
cantly associated with pfmdr1 86Y (P = 0.174), the muta-
tion found associated with CQ-resistant field isolates in
Asia and Africa.
Mutations in antifolate drug resistance genes
Despite relatively recent deployment of antifolate drugs
for controlling malaria in western Kenya, parasites with
mutations in the drug target genes, pfdhfr and pfdhps, were
highly prevalent. The mutation at codon 108 (allele
108N) of the pfdhfr gene, a major determinant of PY resist-
ance, was ubiquitously present in all samples (Table 1). In
addition, mutant alleles at codons 51 and 59 were also
detected at high frequencies (85% – 98%). No mutation
was detected at codons 16, 50, and 164 of pfdhfr. Most
samples (90% – 100%) contained the key SD-resistance
determinant mutation A437G and K540E in pfdhps. In
contrast, the mutant 436F allele was rare (< 5%), and
mutant 436A allele was not detected in any locations. Fur-
ther, no mutation was detected at codons 581 and 613 of
pfdhps.
Increased numbers of mutations at the two antifolate tar-
get genes are associated with increased resistance to SD-
Frequency of mutations in Plasmodium falciparum chloroquine  resistance transporter gene (pfcrt) (A and B), multi-drug  resistance gene (pfmdr1) (C and D) and quintuple mutations  in dihydrofolate reductase (pfdhfr)/dihydropteroate syn- thetase (pfdhps) (E and F) genes in symptomatic and a symp- tomatic volunteers in highland (Kakamega and Kisii) and  lowland (Kombewa) sites of western Kenya Figure 1
Frequency of mutations in Plasmodium falciparum chloroquine 
resistance transporter gene (pfcrt) (A and B), multi-drug 
resistance gene (pfmdr1) (C and D) and quintuple mutations 
in dihydrofolate reductase (pfdhfr)/dihydropteroate syn-
thetase (pfdhps) (E and F) genes in symptomatic and asymp-
tomatic volunteers in highland (Kakamega and Kisii) and 
lowland (Kombewa) sites of western Kenya. The pfdhfr/
pfdhps quintuple mutation refers to 51I/59R/108N/437G/
540E. No mutations were detected at the following codons: 
pfdhfr (A16V, C50R, I164L and S436A), pfdhps (A581G and 
A613S), and pfmdr1 (S1034 and N1042D).
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Table 2: Percentage of haplotypes of P. falciparum parasites 
collected from symptomatic and asymptomatic volunteers in 
western Kenya.
Haplotypes Kombewa Kakamega Kisis
S* A* S A S A
Pfmdr1
86Y/184Y/1246Y 24 26 44 46 38 36
86Y/184F/1246Y 32 34 24 23 16 13
86N/184F/1246D 12 15 0 0 25 27
86Y/184F/1246D 18 10 0 5 1 0
86Y/184Y/1246D 2 0 16 10 1 3
86N/184Y/1246D 6 5 8 10 11 12
86N/184F/1246Y 3543 8 5
86N/184Y/1246Y 3543 0 4
Pfdhfr/pfdhps
Quintuple
51I/59R/108N/437G/540E 87 84 86 83 85 80
Quadruple
51I/59C/108N/437G/540E 7538 4 4
51N/59R/108N/437G/540E 0043 2 6
51I/59R/108N/437G/540K 1 5 1 2 1 2
51I/59R/108N/437A/540E 1100 3 4
Triple
51I/59R/108N/437A/540K 2 3 2 2 5 4
Double
51I/59C/108N/437A/540K 2 2 4 2 0 0
* S – symptomatic; A – asymptomatic; The mutation amino acids are 
underlined.BMC Infectious Diseases 2008, 8:105 http://www.biomedcentral.com/1471-2334/8/105
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PY. In the studied samples, single or double mutations
were rarely encountered, whereas triple mutations in the
pfdhfr gene were the most common. When the two genes
were combined, quintuple mutations (51I/59R/108N of
pfdhfr and 437G/540E of pfdhps) were found with a high
prevalence (80–87%) at the three sites (Fig. 1E and 1F),
followed by quadruple mutations (51I/59C/108N/437G/
540E, 51N/59R/108N/437G/540E, 51I/59R/108N/
437G/540K, 51I/59R/108N/437A/540E) (8% – 16%)
(Table 2).
Mutation frequency difference between asymptomatic 
and symptomatic samples
The pfcrt K76T mutation frequencies were not significantly
different in the asymptomatic and symptomatic samples
in the lowland Kombewa site (96% vs. 94%; Fisher's exact
test, P = 0.537) and two highland sites (86% vs. 92% in
Kakamega, χ2 = 1.41, df = 1, P = 0.235; 80% vs. 83% in
Kisii, χ2 0.03, df = 1, P = 0.863). Similarly, there was no
significantly difference in mutation frequencies of pdmdr1
gene at test codons between asymptomatic and sympto-
matic samples in the lowland (Kombewa: χ2 = 1.44, df =
1, P = 0.230 at codon N86Y; χ2 = 0.33, df = 1, P = 0.566 at
codon Y184F; χ2 = 0, df = 1, P = 1.000 at codon D1246Y)
and two highland sites (Kakamega: χ2 = 0.07, df = 1, P =
0.791 at codon N86Y; χ2 = 0.01, df = 1, P = 0.920 at codon
Y184F; χ2 = 0.26, df = 1, P = 0.610 at codon D1246Y. Kisii:
χ2 = 0.87, df = 1, P = 0.351 at codon N86Y; χ2 = 0, df = 1,
P = 1.000 at codon Y184F; χ2 = 1.40, df = 1, P = 0.237 at
codon D1246Y). Similarly, for the pfdhfr/pfdhps quintuple
mutation frequencies, no significantly difference was
found in the asymptomatic and symptomatic samples in
both lowland site (Kombewa: χ2 = 0.16, df = 1, P = 0.689)
and highland sites (Kakamega: χ2 = 0.20, df = 1, P = 0.655.
Kisii: χ2 = 0.32, df = 1, P = 0.572).
Discussion
In the present study, we analyzed the mutations of four
known drug resistance genes in both highland and low-
land parasite populations of western Kenya. We showed
that the frequencies of key mutations in the pfcrt, pfmdr1,
pfdhps, and pfdhfr genes that were implicated in resistance
to CQ and SP were very high. We further demonstrated
that there was no difference in the frequencies of key
mutations between symptomatic and asymptomatic
malaria volunteers. Our experiment design did not allow
us to test clinical or parasitological efficacy in sympto-
matic infections after treatment; nor was the mutation
prevalence/in vivo resistance before 1998 when the
national policies of treating uncomplicated malaria were
changed to SP was examined. Nevertheless, the big sample
size in this study coupled to lack of differences in the fre-
quency of resistant parasite genotypes in the two highland
areas and the low land area clearly demonstrates a high
frequency of drug resistant mutants circulating in the
study areas.
Resistance to CQ is largely determined by the K76T muta-
tion in the pfcrt gene, and enhanced by mutations at other
sites of this gene and mutations in the pfmdr1 gene. Since
resistant phenotypes often have fitness costs [37], their
prevalence is expected to decline after removal of the
selective pressure. For example, the prevalence of mutant
alleles of pfcrt 76T decreased from 64.5% in 2002 to 16%
in 2004 and that of mutant pfmdr1 86Y alleles decreased
from 46.6% to 2.7% two and half year after CQ with-
drawal in coastal Tanzania [38]. Kublin et al. reported that
the prevalence of the chloroquine-resistant pfcrt 76T gen-
otype decreased from 85% in 1992 to 13% in 2000. In
2001, chloroquine cleared 100% of 63 asymptomatic P.
falciparum infections, no isolates were resistant to chloro-
quine in vitro, and no infections with the chloroquine-
resistant pfcrt 76T genotype were detected [39]. Similarly,
Laufer et al. demonstrated that chloroquine was again an
efficacious treatment for malaria, 12 years after it was
withdrawn from use in Malawi [40]. Although Kenya had
a similar drug policy, the pfcrt K76T mutation in western
Kenya was still predominant. Consistent with the observa-
tion of high pfcrt K76T mutation frequency in the study
sites, pfmdr1 mutations that enhance CQ resistance (e.g.,
86Y) were also present at relatively high frequencies (37.2
– 45.2%) in western Kenya. This may be partly caused by
wide availability and consumption of CQ after it was
replaced as first-line antimalarial drug by antifolate drug
(SP) in 1998 [12,13]. Our results indicated that parasite
populations in western Kenya were still highly resistant to
4-aminoquinoline drugs.
Several years after introduction of SP as the first-line anti-
malarial drug in Kenya, mutant genotypes have already
become common. We found that mutations at codon 108
of the pfdhfr gene and codon 437 of the pfdhps gene, which
are the major determinants for sulfadoxine and pyrimeth-
amine resistance, respectively, were highly prevalent in
our study sites. Furthermore, increased resistance to anti-
folate drugs was correlated with mutations at additional
sites, which were also detected in our present study. In
Kenya, Nzila et al. [41] reported that the pfdhfr  triple
mutant (codons 108, 51 and 59) was associated with
seven-day treatment failure using Fansidar, and this asso-
ciation was strengthened by the presence of double muta-
tions of the pfdhps gene at codons 437 and 540. Such
"quintuple" mutants were also strongly correlated with
Fansidar treatment failure in Malawi [26]. These quintu-
ple mutants have already reached 80–87% prevalence in
the parasite populations in western Kenya. This is consist-
ent with the observation in another highland site in
Chogoria, near Mount Kenya [42]. Since mutations at dif-
ferent sites of the pfdhfr and pfdhps genes might be a step-
wise process, two mutations at codon 59 of pfdhfr and
codon 540 of pfdhps can accurately predict the presence of
this quintuple mutant [26]. The molecular method for
monitoring antifolate resistance in P. falciparum can thusBMC Infectious Diseases 2008, 8:105 http://www.biomedcentral.com/1471-2334/8/105
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be simplified to detect the presence of these two muta-
tions. This method has been shown to provide the best
means of predicting clinical treatment outcomes in the
patient population, which consists primarily of children
from endemic areas of Africa [36]. In our study, either of
these two mutations has exceeded 75% prevalence in the
parasite populations, suggesting that at least 50% of the
parasites carry these double mutations. Consistent with
other genotype studies of pfdhfr from Kenyan isolates, we
did not observe mutations at codon 164 [23,41,43],
although McCollum et al. identified 164L mutation in
several samples in western Kenya [21].
The causes of the malaria epidemics in the East African
highlands are complex and could be the result of interac-
tions between environmental changes, vectors and para-
sites. Antimalarial drug resistance has been invoked as a
major factor [9], however the molecular epidemiology of
drug resistance in these highlands is unknown. Mbaisi et
al. [43] reported a significantly lower prevalence of muta-
tions at codon 437 of the pfdhps gene and codons 86 and
1246 of the pfmdr gene in lowland (Kisumu) samples than
in highland (Kericho, Magadi, and Entosopia) samples in
western Kenya, whereas this trend was the opposite for the
mutation at codon 436 of the pfdhps gene. In contrast, our
study did not detect significant differences in frequency of
mutations at 14 codons in four drug resistant genes
between samples from lowland and highland areas in
western Kenya, although the prevalence of mutations at
codons 86 and 1246 of the pfmdr gene was higher in sam-
ples from the lowlands (Kombewa) than in those from
the highlands (Kakamega and Kisii). This result suggests
either a similar drug selection pressure or significant gene
flow between lowland and highland parasite populations
aided by human travel [44], as detected by microsatellite
and merozoite surface protein 1 and 2 (msp-1 and msp-2)
[45].
Conclusion
Together with the evidence that there was no significance
difference in the frequencies of key resistance-conferring
mutations in pfcrt,  pfmdr1,  pfdhps, and pfdhfr  genes
between symptomatic and asymptomatic malaria infec-
tions in western Kenya highland, high frequencies of these
mutations in symptomatic and asymptomatic infections
suggest that drug resistance of malaria parasites may be an
important contributor to malaria-induced morbidity and
mortality. However, the role of drug resistance as a driving
force for malaria outbreaks in the highlands has not been
established. If drug resistance were the main driving force,
the lowland and highland sites should expect similar epi-
demic pattern of malaria incidence. Moreover, drug resist-
ance level should increase over time until a new
antimalarial drug is adopted. Thus, the number of malaria
patients would be expected to increase gradually over
time, but malaria incidence should not exhibit a large
inter-annual variation. In contrast, dramatic fluctuations
in malaria incidence in the African highlands were
observed [9,46,47]. Significant association between cli-
mate variability and malaria incidence suggests that cli-
mate factors may play an important role in the East
African highlands [47]. Further studies are required to
examine the interactions between climate factors and drug
resistance on malaria incidence in African highlands.
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